Clinical Trial

DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community

Study acronym: DIV-AD
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona. It will also examine how factors such as age, income, education, and health conditions may affect these levels. In addition, the study will identify barriers that may make it difficult to use these blood tests in primary care. The final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.
Trial Details
NCT Number NCT07521722
Lead Sponsor Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Collaborators: Universitat Pompeu Fabra, Hospital del Mar Research Institute (IMIM), Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Hospital del Mar
Conditions Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
Enrollment 250 participants
Start Date 2026-04-27
Primary Completion 2027-04-27 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13